Aynur Oğuz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Aynur Oğuz has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Arzu Okur
Gazi University Faculty of Medicine, Department of Pediatric Hematology and Oncology, Ankara, Türkiye
1 shared publication - Büşra Topuz Türkcan
Gazi University
1 shared publication - Ceyda Eristi Boluk
Department of Ophthalmology, Faculty of Medicine, Gazi University, Ankara, Turkey
1 shared publication - Ceyda Karadeniz
Gazi University
1 shared publication - Faruk Güçlü Pınarlı
Gazi University
1 shared publication - Hatice Tuba Atalay
Gazi University
1 shared publication
Latest Publications
- Open Access
- 2 February 2026
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 61 (2) , 128-138
Evaluation of Retinal Toxicity in Pediatric Oncology Patients Receiving Platinum-Based Chemotherapy
Objective: Improved survival among pediatric oncology patients has increased the burden of late treatment-related complications, including retinal toxicity, a recognized acute and chronic effect of platinum chemotherapy. This study aimed to characterize retinal toxicity associated with platinum agents and compare the toxicities of cisplatin and carboplatin. Materials and Methods: Thirty-six pediatric patients (22 girls, 14 boys) who had completed platinum-based chemotherapy and were in remission were evaluated. Patients with pretreatment ocular disease or impaired renal function were excluded. Oncologic data and ophthalmologic findings including visual acuity, refractive errors, color vision, optical coherence tomography (OCT) (retinal nerve fiber layer thickness [RNFLT]; central foveal retinal thickness [CFRT]), and optical coherence tomography angiography (OCTA) (superficial capillary plexus [SCP]; deep capillary plexus [DCP]) vessel density were obtained retrospectively from medical records. Thirty-six age- and sex-matched healthy children without ocular or systemic disease served as controls. Results: Seventy eyes from the patient group and 72 from controls were analyzed. Time since last chemotherapy was negatively correlated with left-eye CFRT. Higher cumulative cisplatin dose was associated with reduced CFRT and thinning of RNFLT in the nasal-superior quadrant, while carboplatin dose showed no significant effect. Conclusion: Obvious retinal toxicity does not occur with platinum chemotherapy within the dos age range the patients received. The decrease in CFRT and RNFLT with a higher dose of cisplatin suggested that cisplatin may cause more retinal toxicity than carboplatin. The negative correlation between CFRT and duration since last chemotherapy suggests that RNFLT might get thinner over time; therefore, these patients need lifelong ophthalmologic follow-up.
- 2 February 2026
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 61 (2) , 128-138
Open AccessEvaluation of Retinal Toxicity in Pediatric Oncology Patients Receiving Platinum-Based Chemotherapy
Objective: Improved survival among pediatric oncology patients has increased the burden of late treatment-related complications, including retinal toxicity, a recognized acute and chronic effect of platinum chemotherapy. This study aimed to characterize retinal toxicity associated with platinum agents and compare the toxicities of cisplatin and carboplatin. Materials and Methods: Thirty-six pediatric patients (22 girls, 14 boys) who had completed platinum-based chemotherapy and were in remission were evaluated. Patients with pretreatment ocular disease or impaired renal function were excluded. Oncologic data and ophthalmologic findings including visual acuity, refractive errors, color vision, optical coherence tomography (OCT) (retinal nerve fiber layer thickness [RNFLT]; central foveal retinal thickness [CFRT]), and optical coherence tomography angiography (OCTA) (superficial capillary plexus [SCP]; deep capillary plexus [DCP]) vessel density were obtained retrospectively from medical records. Thirty-six age- and sex-matched healthy children without ocular or systemic disease served as controls. Results: Seventy eyes from the patient group and 72 from controls were analyzed. Time since last chemotherapy was negatively correlated with left-eye CFRT. Higher cumulative cisplatin dose was associated with reduced CFRT and thinning of RNFLT in the nasal-superior quadrant, while carboplatin dose showed no significant effect. Conclusion: Obvious retinal toxicity does not occur with platinum chemotherapy within the dos age range the patients received. The decrease in CFRT and RNFLT with a higher dose of cisplatin suggested that cisplatin may cause more retinal toxicity than carboplatin. The negative correlation between CFRT and duration since last chemotherapy suggests that RNFLT might get thinner over time; therefore, these patients need lifelong ophthalmologic follow-up.